idw – Informationsdienst Wissenschaft
Nachrichten, Termine, Experten
Nachrichten, Termine, Experten
In a world first, a research team at the University of Zurich has successfully treated mice carrying an inherited form of epilepsy. The scientists used gene editing to fix faulty DNA directly in the brain cells of mice, which reduced fever-induced seizures and markedly improved survival rates in an animal model. This approach paves the way for future treatment of inherited epilepsy rather than just managing its symptoms.
Epilepsy can have many causes. Where the cause is genetic, the culprit can be a mutation in a gene called SCN1A, which carries the blueprint for a sodium channel in nerve cells and plays a key role in transmitting electrical signals. These neurons normally act as the brain’s brakes, and when that braking system fails, neural networks can become hyperactive and trigger epileptic seizures.
Certain mutations in the SCN1A gene cause an inherited form of epilepsy known as GEFS+. People with GEFS+ suffer from febrile seizures, often beginning in early childhood. Until now, inherited epileptic disorders have been treated with epileptic drugs that reduce the frequency of seizures but often come with side effects. What’s more, not all patients respond well to current treatments.
Correcting mutations directly in the brain
Using a mouse model of GEFS+, a research team led by professors Gerald Schwank and Hanns Ulrich Zeilhofer at the UZH Institute of Pharmacology and Toxicology has now shown for the first time that gene editing can correct such a disease-causing mutation directly in the brain. “The treatment improved communication between nerve cells, significantly reduced the frequency of febrile seizures and increased the survival of the animals,” says Lucas Kissling, a postdoctoral researcher and co-first author of the study.
Gene editing on a molecular level
The researchers took a new approach. “Rather than treating the consequences of the mutation, we wanted to correct the error directly in the gene sequence,” Kissling explains. To achieve this, the team applied a precise gene editing method called prime editing. This technique builds on the gene editing tool CRISPR/Cas and allows isolated genomic errors to be corrected with extreme accuracy, without the need to sever the DNA completely. “That's crucial for nerve cells, which hardly divide and are therefore difficult to access with many conventional gene editing methods,” says Francesca Pietrafesa, a postdoctoral researcher and co-first author of the study.
The researchers worked with mice carrying the same SCN1A mutation found in patients with GEFS+. Like their human counterparts, the animals also developed fever-induced epileptic seizures. After the mice were treated with prime editing, the results were clear: the scientists had successfully corrected the disease-causing mutation in most of the nerve cells in a key region of the brain. The therapy also markedly improved the altered signaling between nerve cells in the brain while sharply decreasing the frequency of febrile seizures. “In the control group, around 80 percent of the animals developed seizures,” says Pietrafesa. “But after undergoing the highly effective prime editing treatment, that figure dropped to around 15 percent.”
Striking at the root cause of disease
This approach is highly promising due to its preservation of the body’s natural gene regulation mechanisms. Rather than delivering an extra copy of the gene, as in conventional gene therapies, it corrects the faulty sequence right at the source. “Even though these are still preclinical findings from a mouse model, the results open up new perspectives – not only for treating SCN1A-linked epilepsy, but potentially also for other neurological diseases caused by a single genetic mutation,” says Kissling.
Dr. Lucas Kissling
Institute of Pharmacology and Toxicology University of Zurich
lucas.kissling@pharma.uzh.ch
+41 44 635 59 23
Dr. Francesca Pietrafesa
francesca.pietrafesa@pharma.uzh.ch
+41 44 635 59 32
Prof. Dr. Gerald Schwank
schwank@pharma.uzh.ch
+41 44 635 59 26
Prof. Dr. Hanns Ulrich Zeilhofer
zeilhofer@pharma.uzh.ch
+41 44 635 59 12
Lucas Kissling, Francesca Pietrafesa et al. Prime editing of a pathogenic Scn1a allele ameliorates seizure phenotypes in a GEFS+ mouse model. Science Translational Medicine. May 13, 2026. DOI: https://doi.org/10.1126/scitranslmed.adz2557
https://www.news.uzh.ch/en/articles/media/2026/gene-editing-epilepsy.html
Prime Editing can be used to specifically correct a disease-causing mutation in the SCN1A epilepsy g ...
Quelle: nccantos
Copyright: University of Zurich
Prime Editing in Mice: A disease-causing mutation in the SCN1A gene disrupts signal transmission in ...
Quelle: Lucas Kissling
Copyright: University of Zurich
Merkmale dieser Pressemitteilung:
Journalisten
Biologie, Medizin
überregional
Forschungsergebnisse, Wissenschaftliche Publikationen
Englisch
Prime Editing can be used to specifically correct a disease-causing mutation in the SCN1A epilepsy g ...
Quelle: nccantos
Copyright: University of Zurich
Prime Editing in Mice: A disease-causing mutation in the SCN1A gene disrupts signal transmission in ...
Quelle: Lucas Kissling
Copyright: University of Zurich
Sie können Suchbegriffe mit und, oder und / oder nicht verknüpfen, z. B. Philo nicht logie.
Verknüpfungen können Sie mit Klammern voneinander trennen, z. B. (Philo nicht logie) oder (Psycho und logie).
Zusammenhängende Worte werden als Wortgruppe gesucht, wenn Sie sie in Anführungsstriche setzen, z. B. „Bundesrepublik Deutschland“.
Die Erweiterte Suche können Sie auch nutzen, ohne Suchbegriffe einzugeben. Sie orientiert sich dann an den Kriterien, die Sie ausgewählt haben (z. B. nach dem Land oder dem Sachgebiet).
Haben Sie in einer Kategorie kein Kriterium ausgewählt, wird die gesamte Kategorie durchsucht (z.B. alle Sachgebiete oder alle Länder).
